What is Janux Therapeutics's other commercial liabilities?

Janux Therapeutics (JANX) reported other commercial liabilities of $15.48M in Q1 2026.

How has Janux Therapeutics's other commercial liabilities changed year-over-year?

Janux Therapeutics's other commercial liabilities increased by 16.0% year-over-year, from $13.34M to $15.48M.

What is the long-term trend for Janux Therapeutics's other commercial liabilities?

Over 5 years (2020 to 2025), Janux Therapeutics's other commercial liabilities has grown at a 88.0% compound annual growth rate (CAGR), from $751K to $17.63M.

Janux Therapeutics JANX Other Commercial Liabilities

Other Commercial Liabilities at other companies

Johnson & JohnsonJNJ

——

AmgenAMGN

——

XencorXNCR

——

Vor BiopharmaVOR

——

Cullinan Therapeutics, Inc.CGEM

——

Nektar TherapeuticsNKTR

——

Other financials

Income statement

See full

Revenue$3.7M—

Operating income-$34.2M+2.0%

Net income-$24.4M-3.6%

EPS (diluted)-$0.39-2.6%

Balance sheet

See full

Cash & equivalents$51.8M-29.7%

Total debt$21.6M-4.6%

Total equity$941.5M-7.0%

Total assets$1.0B-2.1%

Cash flow

See full

Operating cash flow-$12.3M+27.5%

CapEx$273.0K-26.4%

Free cash flow-$12.6M+27.5%

Valuation

See full

Market cap$892.81M-36.1%

Enterprise value$862.55M-35.9%

P/S65×-84.6×

Profitability

See full

Operating margin-1,143.1%-65.1pp

Net margin-833.6%+0.9pp

FCF margin-571.6%+98.3pp

Returns & leverage

See full

Return on equity-11.7%+4.1pp

Debt / equity0×0.0×

Current ratio17×-41.5×

Where this comes from

Reported directly by Janux Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: Janux Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Janux Therapeutics's other commercial liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Janux Therapeutics's other commercial liabilities?: Janux Therapeutics (JANX) reported other commercial liabilities of $15.48M in Q1 2026.
How has Janux Therapeutics's other commercial liabilities changed year-over-year?: Janux Therapeutics's other commercial liabilities increased by 16.0% year-over-year, from $13.34M to $15.48M.
What is the long-term trend for Janux Therapeutics's other commercial liabilities?: Over 5 years (2020 to 2025), Janux Therapeutics's other commercial liabilities has grown at a 88.0% compound annual growth rate (CAGR), from $751K to $17.63M.